Clinical trial · no report yet · Phase 2
NCT05281406
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- NCT05281406 ↗
- Recruiting
- Goethe University
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- NSCLC Stage IIIB; NSCLC Stage IV
- Interventions
- Osimertinib; Pemetrexed; Cisplatin; Carboplatin
- Arms
- Osimertinib in combination with platinum-based chemotherapy · Experimental
- Enrollment
- 50 (estimated)
- Primary outcomes
- Progression Free Survival (PFS1)
- Sponsor
- Goethe University
- Start
- Nov 12, 2021
- Primary completion
- Nov 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05281406 · updated Feb 21, 2025